ENVB - Enveric Biosciences, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Naples,
United States
Type: Equity
ENVB price evolution
ENVB
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.29 | $4.27 | $7.08 | $12.56 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $3.58 | $5.83 | $8.9 | $14.84 |
| Long term investments | ||||
| Property, plant & equipment | $0.51 | $0.54 | $0.6 | $0.68 |
| Goodwill & intangible assets | $0.21 | $0.25 | $0.3 | $0.34 |
| Total noncurrent assets | $0.72 | $0.79 | $0.9 | $1.01 |
| Total investments | ||||
| Total assets | $4.3 | $6.62 | $9.8 | $15.85 |
| Current liabilities | ||||
| Accounts payable | $1.22 | $1.1 | $1.23 | $1.79 |
| Deferred revenue | ||||
| Short long term debt | $0.01 | $0.04 | ||
| Total current liabilities | $2.34 | $4.18 | $4.93 | $4.44 |
| Long term debt | ||||
| Total noncurrent liabilities | $1.01 | |||
| Total debt | $0.01 | $0.04 | ||
| Total liabilities | $2.34 | $4.18 | $4.93 | $5.45 |
| Shareholders' equity | ||||
| Retained earnings | -$96.5 | -$93.06 | -$90.24 | -$83.89 |
| Other shareholder equity | -$0.57 | -$0.54 | -$0.55 | -$0.53 |
| Total shareholder equity | $1.96 | $2.44 | $4.87 | $10.41 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.29 | $17.72 | $17.36 | $1.58 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $3.58 | $18.43 | $17.74 | $2.28 |
| Long term investments | ||||
| Property, plant & equipment | $0.51 | $0.74 | $0.47 | |
| Goodwill & intangible assets | $0.21 | $0.38 | $8.51 | $1.82 |
| Total noncurrent assets | $0.72 | $1.12 | $8.98 | $1.82 |
| Total investments | ||||
| Total assets | $4.3 | $19.55 | $26.72 | $4.1 |
| Current liabilities | ||||
| Accounts payable | $1.22 | $0.46 | $0.68 | $0.68 |
| Deferred revenue | ||||
| Short long term debt | $0.06 | $0.11 | ||
| Total current liabilities | $2.34 | $4 | $2.08 | $0.68 |
| Long term debt | $0.07 | |||
| Total noncurrent liabilities | $2.33 | |||
| Total debt | $0.06 | $0.18 | ||
| Total liabilities | $2.34 | $4.88 | $4.41 | $0.68 |
| Shareholders' equity | ||||
| Retained earnings | -$96.5 | -$79.21 | -$60.74 | -$11.76 |
| Other shareholder equity | -$0.57 | -$0.54 | -$0.03 | -$0.18 |
| Total shareholder equity | $1.96 | $14.67 | $22.31 | $3.42 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $1.37 | $1.35 | $2.51 | $1.99 |
| Selling, general & administrative | $0.93 | $2.01 | $3.16 | $2.78 |
| Total operating expenses | $2.38 | $3.45 | $5.76 | $4.86 |
| Operating income | -$2.38 | -$3.45 | -$5.76 | -$4.86 |
| Income from continuing operations | ||||
| EBIT | -$3.41 | -$2.82 | -$6.36 | -$4.68 |
| Income tax expense | $0.02 | $0.01 | ||
| Interest expense | -$0 | -$0 | -$0 | $0 |
| Net income | ||||
| Net income | -$3.44 | -$2.82 | -$6.36 | -$4.68 |
| Income (for common shares) | -$3.44 | -$2.82 | -$6.4 | -$4.8 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $7.25 | $8.03 | $4.79 | $0.17 |
| Selling, general & administrative | $8.85 | $11.61 | $20.5 | $5.44 |
| Total operating expenses | $16.45 | $27.42 | $64.62 | $5.62 |
| Operating income | -$16.45 | -$27.42 | -$64.62 | -$5.62 |
| Income from continuing operations | ||||
| EBIT | -$17.27 | -$19.95 | -$56.42 | -$6.42 |
| Income tax expense | $0.03 | -$1.49 | -$7.45 | |
| Interest expense | -$0 | $0.01 | $0.01 | $0.45 |
| Net income | ||||
| Net income | -$17.29 | -$18.47 | -$48.98 | -$6.86 |
| Income (for common shares) | -$17.46 | -$18.8 | -$48.98 | -$6.86 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$3.44 | -$2.82 | -$6.36 | -$4.68 |
| Operating activities | ||||
| Depreciation | $0.08 | $0.1 | $0.11 | $0.11 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.36 | $0.37 | $0.88 | $0.53 |
| Total cash flows from operations | -$1.75 | -$2.74 | -$4.47 | -$5.14 |
| Investing activities | ||||
| Capital expenditures | -$0 | $0 | $0.02 | -$0.01 |
| Investments | ||||
| Total cash flows from investing | -$0 | $0 | $0.02 | -$0.01 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$0.19 | -$0.1 | -$1.05 | |
| Effect of exchange rate | -$0.04 | $0.03 | $0.02 | -$0.02 |
| Change in cash and equivalents | -$1.98 | -$2.81 | -$5.48 | -$5.16 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$17.29 | -$18.47 | -$48.98 | -$6.86 |
| Operating activities | ||||
| Depreciation | $0.41 | $0.44 | $0.68 | $0.12 |
| Business acquisitions & disposals | $3.06 | -$0.04 | ||
| Stock-based compensation | $2.15 | $2.62 | $12.6 | $1.98 |
| Total cash flows from operations | -$14.09 | -$17.15 | -$11.46 | -$3.89 |
| Investing activities | ||||
| Capital expenditures | $0.01 | -$0.58 | -$0.19 | |
| Investments | ||||
| Total cash flows from investing | $0.01 | -$0.58 | $2.19 | -$0.04 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $17.22 | $21.61 | $3.86 | |
| Net borrowings | $1.67 | |||
| Total cash flows from financing | -$1.34 | $18.18 | $24.9 | $5.53 |
| Effect of exchange rate | -$0.01 | -$0.08 | $0.14 | -$0.06 |
| Change in cash and equivalents | -$15.44 | $0.37 | $15.78 | $1.53 |
News
Fundamentals
| Market cap | $2.57M |
|---|---|
| Enterprise value | $281.51K |
| Shares outstanding | 2.74M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$16.86M |
| EBIT | -$17.27M |
| Net Income | -$17.29M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.15 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -0.02 |
| EV/EBIT | -0.02 |
| P/S ratio | N/A |
| P/B ratio | 1.02 |
| Book/Share | 0.92 |
| Cash/Share | 0.84 |
| EPS | -$6.31 |
|---|---|
| ROA | -189.13% |
| ROE | -351.59% |
| Debt/Equity | 1.20 |
|---|---|
| Net debt/EBITDA | -0.00 |
| Current ratio | 1.53 |
| Quick ratio | 1.53 |